NCT01539213View on ClinicalTrials.gov

Distribution of Secukinumab (AIN457) Into Dermal Interstitial Fluid After a Single Subcutaneous Administration of 300 mg

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

January 31, 2013

Study Completion Date

January 31, 2013

Conditions
HealthyPsoriasis
Interventions
DRUG

secukinumab (AIN457)

anti-IL-17 antibody

Trial Locations (1)

A-8036

Novartis Investigative Site, Graz

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY

NCT01539213 - Distribution of Secukinumab (AIN457) Into Dermal Interstitial Fluid After a Single Subcutaneous Administration of 300 mg | Biotech Hunter | Biotech Hunter